Viking Therapeutics (VKTX) Income towards Parent Company (2014 - 2026)

Viking Therapeutics has reported Income towards Parent Company for 13 years, with the latest figure at -$263.9 million in Q2 2026.

• Quarterly Income towards Parent Company fell 74.59% year-over-year to -$263.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$982.0 million (down 27.03% YoY) and the FY2025 annual result came in at -$506.2 million, down 60.61% from the prior year.
• Income towards Parent Company rose to -$263.9 million in Q2 2026 per VKTX's latest filing, from -$266.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$17.8 million in Q3 2022 and troughed at -$60.3 billion in Q1 2023.
• A 5-year average of -$7.6 billion and a median of -$235.1 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company plunged 318707.31% in 2023, then soared 99.48% in 2024.
• Over 5 years, Income towards Parent Company stood at -$40.3 million in 2022, then tumbled by 126.06% to -$91.1 million in 2023, then tumbled by 133.47% to -$212.6 million in 2024, then sank by 31.12% to -$278.7 million in 2025, then climbed by 5.33% to -$263.9 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$263.9 million, -$266.4 million, and -$278.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.